Atorvastatin reduces calcification in valve interstitial cells < i > via < /i > the NF- κB signalling pathway by promoting Atg5-mediated autophagy
In conclusion, atorvastatin inhibited the NF- κB signalling pathway by upregulating autophagy, thereby alleviating valve interstitial cell calcification, which was conducive to improving AVC. (Source: European Journal of Histochemistry)
Source: European Journal of Histochemistry - April 12, 2024 Category: Biomedical Science Authors: Menghui Chen, Su Liu Source Type: research
Statin use as a moderator on the association between metformin and breast cancer risk in women with type 2 diabetes mellitus
ConclusionsExtending metformin or statin usage by one year conferred breast cancer protection in women with T2DM. Enhanced protective effect of metformin was observed among those who also use statins. These results suggest the potential of combined metformin and statin therapy as promising breast cancer prevention strategies. (Source: Cancer and Metabolism)
Source: Cancer and Metabolism - April 12, 2024 Category: Cancer & Oncology Source Type: research
The effect of statins on falls and physical activity in people aged 65 and older: A systematic review
ConclusionThis review did not identify a relationship between statin use and physical activity and falls risk in people aged 65 years and older. Ultimately, the risks and benefits of every medication should be considered in the context of each individual. (Source: European Journal of Clinical Pharmacology)
Source: European Journal of Clinical Pharmacology - April 11, 2024 Category: Drugs & Pharmacology Source Type: research
Simvastatin activates the spindle assembly checkpoint and causes abnormal cell division by modifying small GTPases
In this study, we determined its effect on cell division. Cell cycle synchronization experiments revealed a delay in mitotic progression in simvastatin-treated cells at concentrations lower than the IC50. Time-lapse imaging analysis indicated that the duration of mitosis, especially from mitotic entry to anaphase onset, was prolonged. In addition, simvastatin increased the number of cells exhibiting misoriented anaphase/telophase and bleb formation. Inhibition of the spindle assembly checkpoint (SAC) kinase Mps1 canceled the mitotic delay. Additionally, the number of cells exhibiting kinetochore localization of BubR1, an e...
Source: Cellular Signalling - April 11, 2024 Category: Cytology Authors: Junna Tanaka Hiroki Kuwajima Ryuzaburo Yuki Yuji Nakayama Source Type: research
The Effect of Inflammatory Bowel Disease and Irritable Bowel Syndrome on Pravastatin Oral Bioavailability: In vivo and in silico evaluation using bottom-up wbPBPK modeling
AAPS PharmSciTech. 2024 Apr 11;25(4):86. doi: 10.1208/s12249-024-02803-z.ABSTRACTThe common disorders irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD) can modify the drugs' pharmacokinetics via their induced pathophysiological changes. This work aimed to investigate the impact of these two diseases on pravastatin oral bioavailability. Rat models for IBS and IBD were used to experimentally test the effects of IBS and IBD on pravastatin pharmacokinetics. Then, the observations made in rats were extrapolated to humans using a mechanistic whole-body physiologically-based pharmacokinetic (wbPBPK) model. The r...
Source: AAPS PharmSciTech - April 11, 2024 Category: Drugs & Pharmacology Authors: Motasem M Alsmadi Alla A Abudaqqa Nasir Idkaidek Nidal A Qinna Ahmad Al-Ghazawi Source Type: research
Simvastatin activates the spindle assembly checkpoint and causes abnormal cell division by modifying small GTPases
In this study, we determined its effect on cell division. Cell cycle synchronization experiments revealed a delay in mitotic progression in simvastatin-treated cells at concentrations lower than the IC50. Time-lapse imaging analysis indicated that the duration of mitosis, especially from mitotic entry to anaphase onset, was prolonged. In addition, simvastatin increased the number of cells exhibiting misoriented anaphase/telophase and bleb formation. Inhibition of the spindle assembly checkpoint (SAC) kinase Mps1 canceled the mitotic delay. Additionally, the number of cells exhibiting kinetochore localization of BubR1, an e...
Source: Cellular Signalling - April 11, 2024 Category: Cytology Authors: Junna Tanaka Hiroki Kuwajima Ryuzaburo Yuki Yuji Nakayama Source Type: research
The Effect of Inflammatory Bowel Disease and Irritable Bowel Syndrome on Pravastatin Oral Bioavailability: In vivo and in silico evaluation using bottom-up wbPBPK modeling
AAPS PharmSciTech. 2024 Apr 11;25(4):86. doi: 10.1208/s12249-024-02803-z.ABSTRACTThe common disorders irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD) can modify the drugs' pharmacokinetics via their induced pathophysiological changes. This work aimed to investigate the impact of these two diseases on pravastatin oral bioavailability. Rat models for IBS and IBD were used to experimentally test the effects of IBS and IBD on pravastatin pharmacokinetics. Then, the observations made in rats were extrapolated to humans using a mechanistic whole-body physiologically-based pharmacokinetic (wbPBPK) model. The r...
Source: AAPS PharmSciTech - April 11, 2024 Category: Drugs & Pharmacology Authors: Motasem M Alsmadi Alla A Abudaqqa Nasir Idkaidek Nidal A Qinna Ahmad Al-Ghazawi Source Type: research
Simvastatin activates the spindle assembly checkpoint and causes abnormal cell division by modifying small GTPases
In this study, we determined its effect on cell division. Cell cycle synchronization experiments revealed a delay in mitotic progression in simvastatin-treated cells at concentrations lower than the IC50. Time-lapse imaging analysis indicated that the duration of mitosis, especially from mitotic entry to anaphase onset, was prolonged. In addition, simvastatin increased the number of cells exhibiting misoriented anaphase/telophase and bleb formation. Inhibition of the spindle assembly checkpoint (SAC) kinase Mps1 canceled the mitotic delay. Additionally, the number of cells exhibiting kinetochore localization of BubR1, an e...
Source: Cellular Signalling - April 11, 2024 Category: Cytology Authors: Junna Tanaka Hiroki Kuwajima Ryuzaburo Yuki Yuji Nakayama Source Type: research
The Effect of Inflammatory Bowel Disease and Irritable Bowel Syndrome on Pravastatin Oral Bioavailability: In vivo and in silico evaluation using bottom-up wbPBPK modeling
AAPS PharmSciTech. 2024 Apr 11;25(4):86. doi: 10.1208/s12249-024-02803-z.ABSTRACTThe common disorders irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD) can modify the drugs' pharmacokinetics via their induced pathophysiological changes. This work aimed to investigate the impact of these two diseases on pravastatin oral bioavailability. Rat models for IBS and IBD were used to experimentally test the effects of IBS and IBD on pravastatin pharmacokinetics. Then, the observations made in rats were extrapolated to humans using a mechanistic whole-body physiologically-based pharmacokinetic (wbPBPK) model. The r...
Source: AAPS PharmSciTech - April 11, 2024 Category: Drugs & Pharmacology Authors: Motasem M Alsmadi Alla A Abudaqqa Nasir Idkaidek Nidal A Qinna Ahmad Al-Ghazawi Source Type: research
Simvastatin activates the spindle assembly checkpoint and causes abnormal cell division by modifying small GTPases
In this study, we determined its effect on cell division. Cell cycle synchronization experiments revealed a delay in mitotic progression in simvastatin-treated cells at concentrations lower than the IC50. Time-lapse imaging analysis indicated that the duration of mitosis, especially from mitotic entry to anaphase onset, was prolonged. In addition, simvastatin increased the number of cells exhibiting misoriented anaphase/telophase and bleb formation. Inhibition of the spindle assembly checkpoint (SAC) kinase Mps1 canceled the mitotic delay. Additionally, the number of cells exhibiting kinetochore localization of BubR1, an e...
Source: Cellular Signalling - April 11, 2024 Category: Cytology Authors: Junna Tanaka Hiroki Kuwajima Ryuzaburo Yuki Yuji Nakayama Source Type: research
The Effect of Inflammatory Bowel Disease and Irritable Bowel Syndrome on Pravastatin Oral Bioavailability: In vivo and in silico evaluation using bottom-up wbPBPK modeling
AAPS PharmSciTech. 2024 Apr 11;25(4):86. doi: 10.1208/s12249-024-02803-z.ABSTRACTThe common disorders irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD) can modify the drugs' pharmacokinetics via their induced pathophysiological changes. This work aimed to investigate the impact of these two diseases on pravastatin oral bioavailability. Rat models for IBS and IBD were used to experimentally test the effects of IBS and IBD on pravastatin pharmacokinetics. Then, the observations made in rats were extrapolated to humans using a mechanistic whole-body physiologically-based pharmacokinetic (wbPBPK) model. The r...
Source: AAPS PharmSciTech - April 11, 2024 Category: Drugs & Pharmacology Authors: Motasem M Alsmadi Alla A Abudaqqa Nasir Idkaidek Nidal A Qinna Ahmad Al-Ghazawi Source Type: research
The Effect of Inflammatory Bowel Disease and Irritable Bowel Syndrome on Pravastatin Oral Bioavailability: In vivo and in silico evaluation using bottom-up wbPBPK modeling
AAPS PharmSciTech. 2024 Apr 11;25(4):86. doi: 10.1208/s12249-024-02803-z.ABSTRACTThe common disorders irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD) can modify the drugs' pharmacokinetics via their induced pathophysiological changes. This work aimed to investigate the impact of these two diseases on pravastatin oral bioavailability. Rat models for IBS and IBD were used to experimentally test the effects of IBS and IBD on pravastatin pharmacokinetics. Then, the observations made in rats were extrapolated to humans using a mechanistic whole-body physiologically-based pharmacokinetic (wbPBPK) model. The r...
Source: AAPS PharmSciTech - April 11, 2024 Category: Drugs & Pharmacology Authors: Motasem M Alsmadi Alla A Abudaqqa Nasir Idkaidek Nidal A Qinna Ahmad Al-Ghazawi Source Type: research
The Effect of Inflammatory Bowel Disease and Irritable Bowel Syndrome on Pravastatin Oral Bioavailability: In vivo and in silico evaluation using bottom-up wbPBPK modeling
AAPS PharmSciTech. 2024 Apr 11;25(4):86. doi: 10.1208/s12249-024-02803-z.ABSTRACTThe common disorders irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD) can modify the drugs' pharmacokinetics via their induced pathophysiological changes. This work aimed to investigate the impact of these two diseases on pravastatin oral bioavailability. Rat models for IBS and IBD were used to experimentally test the effects of IBS and IBD on pravastatin pharmacokinetics. Then, the observations made in rats were extrapolated to humans using a mechanistic whole-body physiologically-based pharmacokinetic (wbPBPK) model. The r...
Source: AAPS PharmSciTech - April 11, 2024 Category: Drugs & Pharmacology Authors: Motasem M Alsmadi Alla A Abudaqqa Nasir Idkaidek Nidal A Qinna Ahmad Al-Ghazawi Source Type: research
The clinical value of β-blockers in patients with stable angina
Curr Med Res Opin. 2024;40(sup1):33-41. doi: 10.1080/03007995.2024.2317443. Epub 2024 Apr 10.ABSTRACTStable angina, one manifestation of chronic coronary syndrome (CCS), is characterised by intermittent episodes of insufficient blood supply to the myocardium, provoking symptoms of myocardial ischaemia, particularly chest pain. These attacks usually occur during exercise or stress. Anti-ischaemic drugs are the mainstay of pharmacologic management of CCS with symptoms of angina. β-blockers reduce heart rate and myocardial contractility, thus reducing myocardial oxygen consumption. These drugs have been shown to ameliorate t...
Source: Current Medical Research and Opinion - April 10, 2024 Category: Research Authors: Paolo Palatini Jose R Faria-Neto Raul D Santos Source Type: research
Low-dose colchicine for atherosclerosis: long-term safety
Eur Heart J. 2024 Apr 10:ehae208. doi: 10.1093/eurheartj/ehae208. Online ahead of print.ABSTRACTLow-dose colchicine (0.5 mg daily) is now FDA-approved for secondary prevention in patients with coronary disease and will be increasingly prescribed in clinical practice. In this State-of-the-Art Review, data were collated from contemporary systemic reviews of case reports, drug registries, and placebo-controlled trials that assessed specific issues of safety related to the continuous use of colchicine in a range of clinical settings to inform physicians, pharmacists, and patients of the absolute risks of continuous use of low-...
Source: Atherosclerosis - April 10, 2024 Category: Cardiology Authors: Stefan Mark Nidorf Eldad Ben-Chetrit Paul M Ridker Source Type: research
